Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + bevacizumab + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Iparomlimab + tuvonralimab + bevacizumab + paclitaxel + carboplatin is an investigational combination regimen being evaluated as a neoadjuvant therapy for advanced ovarian cancer. This multi-mechanistic regimen combines dual immune checkpoint inhibition with anti-angiogenic therapy and standard cytotoxic chemotherapy. The core immunotherapy component is QL1706, a fixed-ratio mixture of iparomlimab (an anti-PD-1 IgG4 monoclonal antibody) and tuvonralimab (an anti-CTLA-4 IgG1 monoclonal antibody) co-produced from a single host cell line. This is combined with bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF) to inhibit angiogenesis, alongside a chemotherapy backbone of paclitaxel (a microtubule stabilizer) and carboplatin (a DNA alkylating agent). The regimen is currently under evaluation in a Phase II clinical trial sponsored by Fudan University to improve pathological complete response and survival outcomes in patients with advanced ovarian cancer.
- Other names
- iparomlimab + tovorilimab + bevacizumab + paclitaxel + carboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFA (Vascular endothelial growth factor A)DNA
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + bevacizumab + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + bevacizumab + paclitaxel + carboplatin.